Literature DB >> 9918382

Mechanism of the diabetogenic action of cyclosporin A.

L A Menegazzo1, M J Ursich, R T Fukui, D M Rocha, M E Silva, L E Ianhez, E Sabbaga, B L Wajchenberg.   

Abstract

To investigate the mechanism of diabetogenic action of cyclosporin A (CsA), 7 male Wistar albino rats received 10 mg/kg/day of the drug for 4 weeks (CsA). The results were compared with controls (C); blood CsA levels measured weekly remained stable throughout the experiment (mean +/- SEM) (X = 2657.9+/-155.1 ng/ml). Intravenous glucose load (0.75 g/kg) performed after 2 weeks of CsA therapy showed glucose intolerance in treated animals as evaluated by the glucose area under the curve (CsA = 409.2+/-17.8 vs. C = 313.3+/-12.6 umol x ml(-1) x min(-1)) (p < 0.05) with insulin levels being similar in the two groups (CsA = 8603.9+/-1645.5 vs. C = 9571.9+/-828.5 pmol x ml(-1) x min(-1)). After 4 weeks of CsA administration, glucose intolerance was maintained (CsA = 398.6+/-35.6 vs. C = 301.7+/-23.0 umol x ml(-1) x min(-1)) (p < 0.05) associated with a significant decrease in insulin secretion (CsA = 4404.9+/-2392.0 vs. C = 10075.9+/-2861.0 pmol x ml(-1) x min(-1) (p < 0.05). These results suggest that CsA induced a state of insulin resistance preceding the failure of insulin secretion. After 4 weeks, the pancreatic insulin content was also decreased (CsA = 0.7+/-0.1 vs. C = 1.4+/-0.5 mU/mg) (p < 0.05). Maximal insulin binding to isolated adipocytes was not affected by CsA (CsA = 7.4+/-2.6 vs. C = 6.4+/-2.0%), although glucose transport and oxidation decreased after CsA treatment (p < 0.05). In conclusion, glucose intolerance induced by CsA in Wistar albino rats is due to decreased insulin production and impaired insulin action by a post-binding mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9918382     DOI: 10.1055/s-2007-978954

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

1.  Novel views on new-onset diabetes after transplantation: development, prevention and treatment.

Authors:  Manfred Hecking; Johannes Werzowa; Michael Haidinger; Walter H Hörl; Julio Pascual; Klemens Budde; Fu L Luan; Akinlolu Ojo; Aiko P J de Vries; Esteban Porrini; Giovanni Pacini; Friedrich K Port; Adnan Sharif; Marcus D Säemann
Journal:  Nephrol Dial Transplant       Date:  2013-01-17       Impact factor: 5.992

Review 2.  Challenges in the diagnosis and management of new-onset diabetes after transplantation.

Authors:  Moro O Salifu; Fasika Tedla; Preethi V Murty; Serhat Aytug; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

Review 3.  Diabetes and kidney transplantation: past, present, and future.

Authors:  Giselle Guerra; Amna Ilahe; Gaetano Ciancio
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 4.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

5.  Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation.

Authors:  Fu L Luan; Linda J Stuckey; Akinlolu O Ojo
Journal:  Transplantation       Date:  2010-04-27       Impact factor: 4.939

6.  Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation.

Authors:  H A Chakkera; R L Hanson; S M Raza; J K DiStefano; M P Millis; R L Heilman; D C Mulligan; K S Reddy; M J Mazur; K Hamawi; A A Moss; K L Mekeel; J R Cerhan
Journal:  Transplant Proc       Date:  2009-12       Impact factor: 1.066

Review 7.  The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings.

Authors:  Behzad Einollahi; Mohsen Motalebi; Mahmood Salesi; Mehrdad Ebrahimi; Mehrdad Taghipour
Journal:  J Nephropathol       Date:  2014-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.